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The integral role of positron-emission tomography (PET) using the glucose analog tracer
ﬂuorine-18 ﬂuorodeoxyglucose (FDG) in the staging of non-small cell lung cancer (NSCLC)
is well established. Evidence is emerging for the role of PET in response assessment to
neoadjuvant therapy, combined-modality therapy, and early detection of recurrence. Here,
we review the current literature on these aspects of PET in the management of NSCLC.
FDG-PET, particularly integrated 18F-FDG-PET/CT, scans have become a standard test in the
staging of local tumor extent, mediastinal lymph node involvement, and distant metastatic
disease in NSCLC. 18F-FDG-PET sensitivity is generally superior to computed tomography
(CT) scans alone. Local tumor extent and T stage can be more accurately determined
with FDG-PET in certain cases, especially in areas of post-obstructive atelectasis or low
CT density variation. FDG-PET sensitivity is decreased in tumors <1 cm, at least in part
due to respiratory motion. False-negative results can occur in areas of low tumor burden,
e.g., small lymph nodes or ground-glass opacities. 18F-FDG-PET-CT nodal staging is more
accurate than CT alone, as hilar and mediastinal involvement is often detected ﬁrst on
18F-FDG-PET scan when CT criteria for malignant involvement are not met. 18F-FDG-PET
scans have widely replaced bone scintography for assessing distant metastases, except
for the brain, which still warrants dedicated brain imaging. 18F-FDG uptake has also been
shown to vary between histologies, with adenocarcinomas generally being less FDG avid
than squamous cell carcinomas. 18F-FDG-PET scans are useful to detect recurrences, but
are currently not recommended for routine follow-up. Typically, patients are followed with
chest CT scans every 3–6 months, using 18F-FDG-PET to evaluate equivocal CT ﬁndings.
As high 18F-FDG uptake can occur in infectious, inﬂammatory, and other non-neoplastic
conditions, 18F-FDG-PET-positive ﬁndings require pathological conﬁrmation in most cases.
There is increased interest in the prognostic and predictive role of FDG-PET scans. Studies
show that absence of metabolic response to neoadjuvant therapy correlates with poor
pathologic response, and a favorable 18F-FDG-PET response appears to be associated with
improved survival. Further work is underway to identify subsets of patients that might
beneﬁt individualized management based on FDG-PET.
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INTRODUCTION
Lung cancer is the leading cause of cancer death in the USA and
worldwide. In 2009, there were an estimated 1,608,800 cases and
1,348,400 deaths due to lung cancer globally (Jemal et al., 2011),
and it is estimated that there will be 226,160 new cases and 160,
340 deaths attributable to lung cancer in the USA in 2012 (Siegel
et al., 2012).
The management of non-small cell lung cancer (NSCLC) often
requires a multimodality approach to accurately diagnose, stage,
and treat patients. Some of the most important advances in the
treatment of lung cancer have been the development and imple-
mentation of accurate and functional imaging. The advent of
positron-emission tomography (PET) and computed tomography
(CT) scanning has revolutionized the treatment of lung can-
cer, and each has become integral in the staging and treatment
of NSCLC. The purpose of this article is to review the role of
ﬂuorodeoxyglucose (FDG)-PET scans in the diagnosis, staging,
response assessment, and follow-up of patients treated forNSCLC.
While several non-18F-FDG-PET radiotracers show promise in
preclinical and early clinical evaluation, we have limited the scope
of this review to 18F-FDG-PET as this is the most widely used,
clinically relevant and extensively studied form of PET in the
management of NSCLC.
DIAGNOSIS AND EVALUATION OF LUNG LESIONS
In the primary evaluation of pulmonary lesions, FDG-PET scans
are useful to distinguish between benign andmalignant etiologies.
Although numerous non-malignancy related conditions within
the lungs take up FDG, including infection and inﬂammation,
extensive work has been done in correlating FDG-PET posi-
tivity with pathological malignancy. A meta-analysis of studies
investigating the accuracy of FDG-PET in diagnosing malignant
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pulmonary lesions estimated the sensitivity and speciﬁcity to be
96.8 and 77.8%, respectively (Gould et al., 2001). A separate
meta-analysis found the sensitivity, speciﬁcity, and accuracy of
18F-FDG-PET in the diagnosis of lung lesions to be 96, 80, and
91% (Hellwig et al., 2001). In the same analysis, 18F-FDG-PET
was superior to CT in the evaluation of nodal and distant metas-
tasis, and changed therapeutic management in 18% of all of the
cases studied.
Positron-emission tomography is particularly useful in differ-
entiating benign from malignant obstructions in the setting of
atelectasis. A retrospective study of 84 patients demonstrated a
signiﬁcantly higher sensitivity with 18F-FDG-PET/CT compared
with CT alone in the detection of atelectasis-associated malignant
lesions (91 vs 48%, p < 0.001; Cho et al., 2011). The authors
concluded that, because FDG uptake was signiﬁcantly higher in
malignant lesions, PET can potentially reduce the number of
unnecessary invasive procedures and more accurately select those
patients with atelectasis that require further workup.
Positron-emission tomography has been shown to be less sensi-
tive for the characterization of smaller lung lesions. This may be at
least in part due to respiratory motion, which artiﬁcially decreases
the FDG signal (Figure 1). Motion artifact can cause a signiﬁcant
underestimation of 18F-FDG uptake, which is commonly quan-
tiﬁed with a parameter called the maximum standardized uptake
value, or SUVmax (Liu et al., 2009).
Toba et al. (2010) showed the positive predictive value (PPV)
of FDG-PET to be signiﬁcantly lower with lesions <1 cm in size
compared with larger lesions (0.36 vs 0.90, p = 0.015). The lower
PPVof smaller lesions reﬂects a higher rate of falsely positive FDG-
PET scans. An example of a false-positive lung nodule is shown in
Figure 2.
In addition to the evaluation of primary lung lesions and
the determination of malignant involvement, PET may also offer
insight into the histology of the imaged malignancy. Correlations
of pathology with the SUVmax of tumors on preoperative imaging
FIGURE 1 | Lung cancer patient with multiple right lung nodules.
Shown are corresponding PET (left ), CT (right ), and fusion (middle) images
of a single coronal plane through the right lung. In the upper lobe, where
respiratory motion is least, a punctate nodule (white arrowheads)
demonstrates intense FDG uptake with a distinctly focal appearance (black
arrowhead). In the lower region of the lung, where respiratory motion is
greater, the FDG uptake of larger nodules (white arrows) appears relatively
less-intense – probably due to “spreading” of the activity over a spatial
volume during each breathing cycle, a kind of respiratory artifact. This
“spreading” is most visually evident closest to the diaphragm (black arrow).
FIGURE 2 | Eighty-two-year-old female with growing right lung
nodule. Prior lung CT scans over a 1-year period had demonstrated
increasing size of a spiculated-appearing right lung nodule (white arrow).
FDG-PET/CT was performed for nodule characterization. Images show
corresponding transaxial planes through the chest from the CT and FDG
PET (upper right ); and a 3D maximum intensity projection imaged centered
on the chest region (center image). PET showed detectable, albeit minimal,
activity in the right lung nodule (black arrows; SUVmax 2.1) and focal activity
in the right pulmonary hilum (arrowhead) thought to represent lymph node
FDG uptake.Wedge resection was performed; pathology found focal
bronchopneumonia/granuloma.
have shown bronchioalveolar carcinoma and well-differentiated
tumors to be less 18F-FDG-avid (Vesselle et al., 2008) and squa-
mous cell carcinomas to have a consistently higher 18F-FDG
uptake compared with other histologies (Aquino et al., 2007; de
Geus-Oei et al., 2007). This additional characterization of lesions
by PET may be able to distinguish synchronous primary tumors
frommetastatic disease, and offer prognostic information beyond
what is gathered with CT-based imaging.
STAGING OF THE MEDIASTINUM
Beyond the evaluation of the primary tumor, the accurate stag-
ing of the mediastinal lymph nodes is critically important in
the management of NSCLC. The presence of mediastinal lymph
node involvement changes the management approach to multi-
modality therapy including chemotherapy, surgery, and radiation
therapy, while early-stage node-negative lung cancer is usually
treated with a single local treatment modality focusing on the
primary parenchymal lung lesion only, such as surgical resection
or stereotactic body radiation therapy (SBRT).
Numerous retrospective studies have investigated the ability of
PET to detect lymph node metastases. A single institutional com-
parison of CT and 18F-FDG-PET/CT staging of the mediastinum
in relation to pathological ﬁndings showed 18F-FDG-PET/CT to
have superior sensitivity, speciﬁcity, accuracy, positive and nega-
tive predictive value (Yang et al., 2008). Li et al. (2012) reported an
excellent negative predictive value of 18F-FDG-PET (91%) in the
evaluation of early stage T1-2N0 tumors. A meta-analysis of 39
studies found superior sensitivity and speciﬁcity for lymph node
involvement based on 18F-FDG-PET when compared with CT.
Sensitivity and speciﬁcity were 85 and 90%, for 18F-FDG-PET,
and 61 and 79% for CT, respectively (Gould et al., 2003). Another
meta-analysis (Lv et al., 2011) conﬁrmed the excellent speciﬁcity of
FDG-PET in the staging of the mediastinum (95%), although the
authors reported a lower sensitivity (68%) than other comparable
studies.
The comparison between PET and CT has also been investi-
gated in the prospective setting. Scott et al. (1996) enrolled 27
patients with known or suspected NSCLC to undergo both a CT
and 18F-FDG-PET scan, and compared the modalities in their
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ability to detect N2 and N3 metastasis, which was assessed by
surgical conﬁrmation. CT had a sensitivity of 60%, a speciﬁcity
of 93%, and a PPV of 60%, whereas 18F-FDG-PET in con-
junction with CT was 100% sensitive, 98% speciﬁc, and had a
PPV of 91%. A similarly designed, larger study from Belgium
conﬁrmed the superiority of 18F-FDG-PET added to CT in the
accurate staging of N2/N3 metastasis (Vansteenkiste et al., 1998).
Pieterman et al. (2000) reported a sensitivity and speciﬁcity of
91 and 86% for 18F-FDG-PET compared with 75 and 66% for
CT. A multicenter prospective investigation from Japan similarly
demonstrated a statistically signiﬁcant improvement in the accu-
racy and speciﬁcity of integrated 18F-FDG-PET/CTwith amodern
hybrid scanner over standard CT alone in the evaluation of medi-
astinal lymph nodes (Kubota et al., 2011). A summary of the
studies that have evaluated the performance of 18F-FDG-PET
and 18F-FDG-PET/CT in evaluating the mediastinum is shown
in Table 1.
An interesting caveat to the superior performance of 18F-FDG-
PET/CT in the evaluation of the mediastinum was reported by a
study from Ireland (Al-Sarraf et al., 2008). In their retrospective
review of 206 patients and 1145 lymph nodes, the authors strat-
iﬁed lymph nodes by size and found that 18F-FDG-PET/CT had
a signiﬁcantly lower speciﬁcity and accuracy for nodes >1 cm
as compared to <1 cm, illustrating the higher possibility of
false positivity with large lesions. Importantly, 18F-FDG-PET/CT
for large lymph nodes still performed better than CT alone.
These ﬁndings were consistent with Shiraki et al. (2004), who
reported that false-positive nodes were signiﬁcantly larger than
true-negative nodes as staged by FDG-PET. These studies illustrate
an important limitation of FDG-PET/CT, and reafﬁrm that FDG-
PET-positive lymph nodes still require pathological conﬁrmation
by mediastinoscopy.
DETECTION OF DISTANT METASTASIS
The need for accurate staging of patients with NSCLC applies
not only to the mediastinum but also to the evaluation for dis-
tant metastatic disease. Historically, bone scintigraphy had been
a mainstay in the initial evaluation of NSCLC due to the tumor’s
propensity to spread to the bones. Recently, several efforts have
shown that 18F-FDG-PET/CT offers superior rates of detection
and has obviated the need for bone scans at presentation.
18F-FDG-PET/CT is particularly effective at detecting bone
metastasis, with one study reporting a sensitivity, speciﬁcity, and
accuracy of 93.9, 98.9, and 97.8% (Liu et al., 2010). A compari-
son of technetium 99m-methylene diphosphonate (99mTc-MDP)
bone scintigraphy to 18F-FDG-PET/CT was ﬁrst described by
Bury et al. (1998), who showed a higher accuracy with 18F-FDG-
PET in the detection of osseous metastasis. These ﬁndings have
been corroborated by other reports (Hsia et al., 2002; Gayed
et al., 2003; Cheran et al., 2004). A German study of lung can-
cer patients compared integrated 18F-FDG-PET/CT versus two
types of bone scans – a standard two-dimensional “planar” bone
scan with 99mTc-MDP and a three-dimensional bone PET scan
with the bone-tracer ﬂuorine-18 ﬂuoride (18F-PET) – a different
tracer from 18F-FDG-PET that has become increasingly avail-
able worldwide. The investigators reported that 18F-FDG-PET/CT
performed with a lower sensitivity than the 18F-PET bone scan,
but was superior to conventional 99mTc-MDP bone scintigraphy
(Kruger et al., 2009). However, neither of the bone tracers – 18F-
PET nor 99mTc-MDP scintigraphy – can distinguish viable tumor
from treated disease, whereas the metabolism tracer 18F-FDG-
PET is muchmore speciﬁc for viable tumor. Even when combined
with testing of alkaline phosphatase levels, which is often ele-
vated in patients with bone metastasis, 99mTc-MDP bone scan
still performs inferiorly to 18F-FDG-PET/CT (Min et al., 2009).
An important limitation to the ability of FDG-PET to detect neo-
plastic disease is the potential for false positivity, as numerous
benign conditions (including trauma, infection, and physiological
variants) are associated with a substantial amount of radiotracer
uptake. The question was most thoroughly answered by a recent
meta-analysis of 17 studies comparing 18F-FDG-PET/CT, 18F-
FDG-PET, MRI, and bone scintography. The pooled sensitivity
of each of the modalities in the detection of metastasis was 92,
87, 77, and 86%; the speciﬁcity was 98, 94, 92, and 88%, respec-
tively. When analyzed by diagnostic odds ratio, 18F-FDG-PET/CT
(2014.9) was signiﬁcantly superior to 18F-FDG-PET (75.26), MRI
(161.2), and bone scintography (37.85; Qu et al., 2012).
FDG-PET is also accurate overall in the detection of extra-
osseous distant metastases. In the same study demonstrating the
superiority of 18F-FDG-PET in stagingof themediastinum,Pieter-
man et al. (2000) reported on the high sensitivity and speciﬁcity
of 18F-FDG-PET in the detection of distant metastases alone (92
Table 1 | Performance of PET and PET/CT in detection of mediastinal lymph node metastasis.
No. of patients Sensitivity (%) Specificity (%) Accuracy (%) Positive predictive
value (%)
Negative predictive
value (%)
Scott et al. (1996) 27 100 98 – 91 –
Vansteenkiste et al. (1998) 68 93 95 94 – –
Pieterman et al. (2000) 102 91 86 – – –
Gould et al. (2003) 3078 85 90 – – –
Yang et al. (2008) 122 86 85 85 64 95
Lv et al. (2011) 2550 68 95 – – –
Kubota et al. (2011) 81 87.2 72.5 77.8 – –
Li et al. (2012) 200 44 83 78 29 91
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and 83%), and 11% of patients in their study had distant metas-
tases detected by 18F-FDG-PET that other modalities had failed
to detect. The use of PET appears to be particularly important in
the workup of patients with locally advanced NSCLC who may
be offered curative therapy, as one study reported 24% of patients
with clinical stage III cancer had previously undetected distant
metastases when evaluated by 18F-FDG-PET (Mac Manus et al.,
2001). This phenomenon of stage migration has been well docu-
mented (Chee et al., 2008; Farjah et al., 2009; Dinan et al., 2012)
and most likely contributes to the association of 18F-FDG-PET
with improved overall survival in patients with NSCLC.
In the characterization of adrenal lesions found by CT or MRI,
18F-FDG-PET has excellent sensitivity, speciﬁcity, and accuracy
(100, 94, 96%, respectively; Yun et al., 2001); however, an FDG-
avid adrenal nodule can represent a hyper-functioning adenoma.
If the ﬁnding of an FDG-avid adrenal lesion potentially impacts
patient care, then further characterization of the adrenal lesion
should be considered, including the use of biochemical assays of
adrenal function and/or adrenal-protocol CT or MRI studies and
pathologic conﬁrmation.
Because of the high background 18F-FDG uptake of normal
brain parenchyma, the ability of PET to detect brain metastasis
is limited. When compared with other imaging modalities, 18F-
FDG-PET appears to offer no additional information regarding
the presence of metastatic disease in the brain (Palm et al., 1999;
Posther et al., 2006). The current standard of care for all patients
with clinical stage ≥ IB is to evaluate the brain with a dedicated
MRI of the brain (Ettinger et al., 2010), and there is currently
no indication that 18F-FDG-PET/CT will be able to replace this
diagnostic test.
PREDICTION AND EVALUATION OF RESPONSE
Beyond the initial staging, 18F-FDG-PET may be useful in
the prediction of response to therapy. By offering information
regarding metabolic activity in addition to structural appearance,
18F-FDG-PET can more accurately characterize lesions prior to
therapy. Furthermore, due to treatment effects after neoadjuvant
chemotherapy and radiation therapy, including shrinkage of dis-
ease burden and radiation-induced inﬂammation and ﬁbrosis, CT
is limited in its ability to accurately predict prognosis after ini-
tial therapy, whereas 18F-FDG-PET may offer a more accurate
evaluation of initial response.
PREDICTION OF RESPONSE AFTER SBRT FOR EARLY-STAGE NSCLC
For early stage tumors, SBRT has been widely adopted as an alter-
native to surgical resection inmedically inoperable patients. There
are mixed data regarding the utility of pretreatment 18F-FDG-
PET scans in the prediction of response to SBRT. Clarke et al.
(2012) retrospectively showed that higher pretreatment SUVmax
was associated with worse recurrence-free survival and a higher
rate of distant failure in patients with stage I lung cancer treated
with SBRT. A larger study by Takeda et al. (2011) showed signiﬁ-
cantly higher local control rates for lower SUVmax in patients with
localized, node-negative lung cancer treated with SBRT.
In contrast, a similar study with a shorter median follow-up of
16.9 months showed no signiﬁcant correlation with SUVmax and
mediastinal failure, distant failure, or overall survival (Burdick
et al., 2010). A study from Indiana University with a much longer
follow-up of 42.5 months also showed no correlation between
pretreatment SUVmax and local control or overall survival, but the
pretreatment SUVmax was only available for 55% of the patients
studied (Hoopes et al., 2007). A prospective study evaluated 39
tumors treated with SBRT and followed with CT and 18F-FDG-
PET, and while both imaging modalities were useful in evaluating
local radiographic and metabolic response, further analysis is
needed to correlate these responses with long term treatment
outcomes (Mohammed et al., 2011).
PREDICTION OF RESPONSE AFTER DEFINITIVE SEQUENTIAL OR
CONCURRENT CHEMORADIATION IN INOPERABLE PATIENTS
For patients with unresectable disease treated with chemother-
apy or chemoradiation, studies evaluating the prognostic value
of pretreatment 18F-FDG-PET scans are limited by heterogenous
patient populations that are ultimately treated with a wide range
of modalities. A meta-analysis of 13 studies and 1474 patients
showed high pretreatment SUV to be a statistically signiﬁcantly
poor prognostic factor for survival; however, the majority of
the studies included patients with any stage (I–IV) disease, and
SUV threshold determinations were often arbitrary and differed
among authors (Berghmans et al., 2008). A slightly more homoge-
nous population was retrospectively investigated by Hoang et al.
(2008) who demonstrated no signiﬁcant correlation between pre-
treatment 18F-FDG uptake and survival among 214 patients with
stage III–IV NSCLC, the majority of whom were not treated with
surgery.
Post-treatment 18F-FDG-PET and CT have been compared in
a prospective manner in patients treated with deﬁnitive radia-
tion or chemoradiation, and 18F-FDG-PET response was found
to be more signiﬁcantly correlated with survival than response as
assessed by CT (Mac Manus et al., 2003). Other studies have con-
ﬁrmed a poorer prognosis in patients with a higher volume of
residual metabolically active tumor after deﬁnitive treatment (Lee
et al., 2012).
Induction chemotherapy (IC) can be used as neoadjuvant ther-
apy prior to consolidative radiotherapy. Decoster et al. (2008)
studied 31 patients that were treated with IC for unresectable stage
III disease. Patients received a baseline 18F-FDG-PET andCT scan,
and scans were repeated after three cycles of IC. Response by FDG-
PET and byCTwas correlatedwith time to progression and overall
survival. The authors showed that a complete response (CR) by
18F-FDG-PET after IC is associatedwith a signiﬁcantly longer time
to progression (p = 0.026) and overall survival (p = 0.004) than
non-CRs, and those with a partial response had a longer time
to progression but only a trend toward longer survival compared
with non-responders. These ﬁndings demonstrate the ability of
18F-FDG-PET to offer accurate prognostic and predictive infor-
mation for patients undergoing IC that cannot undergo surgical
resection.
INDUCTION CHEMOTHERAPY PRIOR TO PREOPERATIVE
CHEMORADIATION THERAPY
In selected patients, there may be a role for neoadjuvant ther-
apy for locally advanced, potentially resectable NSCLC. While the
optimal regimen in this setting is unclear, two commonly applied
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options include IC followed by surgery, or preoperative chemora-
diation and surgery. Investigators have shown 18F-FDG-PET to
be a useful predictor of both pathological and clinical response in
patients treatedwith ICprior to preoperative conformal radiother-
apy (CRT). A German study showed that the percentage decrease
in SUVmax on serial 18F-FDG-PET scans obtained for initial stag-
ing, after IC, and after CRT, was signiﬁcantly correlated with
histopathological response in patients that ultimately underwent
surgical resection (Pottgen et al., 2006). In another study, patients
that underwent a similar sequence of treatment were evaluated
with both a staging 18F-FDG-PET and a restaging 18F-FDG-PET
after the completion of IC and CRT. Survival was signiﬁcantly
longer for patients who experienced a reduction of >80% of the
original average SUV,deﬁned as the (SUVmax + SUVof surround-
ing background structures)/2. Those patients who had only a
partial response or progressive disease had a signiﬁcantly worse
outcome (Eschmann et al., 2007). These results were conﬁrmed
by Choi et al. (2002) who showed residual 18F-FDG uptake after
preoperative chemoradiation therapy to be signiﬁcantly correlated
with the degree of pathological response.
Several non-18F-FDG-PET radiotracers show promise in the
evaluation of treatment response, due to their ability to charac-
terize unique aspects of tumor behavior such as DNA synthesis,
hypoxia, amino acid use, and hormone receptor expression (Dun-
phy and Lewis, 2009). In conjunction with information about
glucose metabolism offered by FDG-based PET, these tracers may
offer more comprehensive and speciﬁc information about tumor
characteristics and predicted response to therapy in the future.
In summary, the ability of FDG-PET to offer predictive and
prognostic information regarding the response to initial therapy
is well documented, and can aid in the proper selection of patients
that are most likely to beneﬁt from further therapy in the form of
surgery or radiation.
FOLLOW-UP AND SURVEILLANCE
There is limited data regarding the role of 18F-FDG-PET in the
long-term follow-up of patients treated with deﬁnitive therapy
for NSCLC, and routine surveillance PET scans are not recom-
mended (Ettinger et al., 2010). However, many benign conditions,
including atelectasis, consolidation, and radiation ﬁbrosis, are dif-
ﬁcult to distinguish from locoregional recurrence on standard CT
imaging (Lever et al., 1984). In these settings, 18F-FDG-PET is use-
ful in not only accurately identifying true malignant relapse but
also offering prognostic information. Hicks et al. (2001) reported
18F-FDG-PET’s sensitivity for relapse as 98%, speciﬁcity as 82%,
and overall accuracy as 93%, with 18F-FDG-PET negativity being
highly predictive of better survival. When feasible, PET-positive
areas should be corroborated with pathological analysis, as benign
conditions including inﬂammation and ﬁbrosis can exhibit hyper-
metabolic activity. An example of recurrence of distant metastasis
as seen by 18F-FDG-PET is shown in Figure 3.
FDG-PET is useful for detecting recurrence after SBRT, as
higher SUVs on scans obtained more than 6 months after
treatment have been shown to be associated with higher local
recurrence rate (Zhang et al., 2012). An important ﬁnding in this
study was that treated areas may remain persistently hyperme-
tabolic, leading to the inability to detect local recurrence; SUVs
FIGURE 3 | Sixty-seven-year-old male with stage IV non-small cell lung
cancer.Top row : 3D maximum intensity projection (MIP) FDG-PET images
obtained at baseline (left ); after 4 months treatment with pemetrexed and
bevacizumab (middle); and 9 months after the baseline scan, switched to
second-line docetaxel therapy due to progression on interim scans (right ).
Arrowheads point to an FDG-avid osseous metastasis in the left ilium that
initially disappears in response to treatment but then recurs. Middle row :
corresponding CT (left ) and PET (right ) images of a single transaxial plane
through the pelvis, showing the lesion of the left ilium on CT that showed
no FDG-avidity after 4 months treatment with pemetrexed and
bevacizumab, suggesting a treated disease (arrowheads). Bottom row : the
subsequent scan, 9 months after baseline, showed no change in the CT
appearance of the left iliac bone lesion, but the lesion now demonstrates
intense FDG uptake, consistent with a viable/recurrent metastasis.
from 18F-FDG-PET scans done within 6 months of treatment
were not correlated with local recurrence. A similar phenomenon
was observed in the study by Hoopes et al. (2007), who reported
that several patients had moderately hypermetabolic activity but
no evidence of local, nodal, or distant recurrence as seen on scans
performed 2 years after treatment. This persistent uptake may be
due to the unique reaction within tissue and tumor after SBRT,
including more persistent inﬂammation and ﬁbrosis compared
with conventional fractionation. As the use of this modality con-
tinues to increase, further study is warranted to investigate the
role of FDG-PET in the evaluation, treatment, and follow-up of
patients treated with SBRT.
CONCLUSION
FDG-PET, particularly current state-of-the-art FDG-PET/CT,
plays an instrumental role in all phases of the management of
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lung cancer offering superior accuracy in the diagnosis of lung
tumors, detection of nodal and distant metastasis, and delin-
eation of T stage compared with other modalities. Importantly,
18F-FDG-PET is less accurate with lesions <1 cm in the lung and
lesions that exhibit signiﬁcantmotion.While still superior in accu-
racy to other modalities overall, these limitations warrant further
investigation of sub-centimeter, 18F-FDG-PET-negative lesions,
in most cases. Pathological evaluation of 18F-FDG-PET-positive
lesions is necessary given the possibility for false-positive ﬁndings.
FDG-PET scans also offer predictive and prognostic information
after both neoadjuvant and deﬁnitive therapy and are useful in the
workup of suspected recurrences. The increased use of FDG-PET
scans will contribute to the more accurate selection of patients
for appropriate treatment, which may improve outcomes and
help avoid toxic therapies that are unlikely to provide beneﬁt to
patients.
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